Immutep Ltd.

Immutep’s combination of its LAG-3 protein/MHC (major histocompatibility complex) Class II agonist eftilagimod alfa and Merck & Co.’s immuno-oncology blockbuster Keytruda (pembrolizumab) has shown

Immutep’s eftilagimod alpha has not so much beaten Keytruda as joined it. An investigator-initiated study has shown that addition of the LAG-3 immunotherapy to the standard-of-care first-line non-smal

The theory that LAG-3 inhibitors could help improve survival for colorectal cancer patients has suffered another setback with the failure of a late-stage trial evaluating Merck & Co., Inc. 's favezel

2025 will see a continuation in the steady growth of pharmaceutical product sales, according to consensus forecast data from Evaluate. This trend of incremental growth was interrupted between 2021 and